Allied Market Research

Global Cefetamet Pivoxil Tablets Market - Opportunities and Industry Forecasts, 2017-2023

The report provides information about the current and upcoming trends in the market from 2016 to 2023, which helps determine the prevailing opportunities.


Portland, OR -- (SBWIRE) -- 09/18/2017 -- Cefetamet is an antibacterial broad spectrum Cephalosporin antibiotic prescribed for susceptible infections. Cefetamet has in-vitro activity against bacteria, such as Haemophilus influenza, Streptococcus pneumoniae, Moraxella catarrhalis, and others, by inhibiting bacterial cell wall synthesis.

Access to the full summary:

The major factors driving the cefetamet pivoxil tablets market are increase in prevalence of bacterial infections, innovative R&D approaches to develop advanced antibiotics, various initiatives taken by government to spread awareness about infections, and technological advancements in field of biochemistry. However, side effects associated with drug and ignorance toward the infectious diseases are projected to impede the market growth. The developments by various healthcare agencies in rise in awareness amongst the population of untapped market provides numerous opportunities in near future.

Cefetamet Pivoxil Tablets Market Key Segments:

By Age Group

- 6 Months3 Years
- 39 Years
- 912 Years
- Over 12 Years

By Application

- Ear, Nose and/or Throat Infections
- Otitis Media
- Sinusitis
- Pharyngo-Tonsillitis
- Lower Respiratory Tract Infections
- Acute Bacterial Exacerbation of Chronic Bronchitis
- Tracheo-Bronchitis
- Pneumonia
- Urinary Tract Infections
- Gonococcal Urethritis in Men
- Others

The key players operating in this market include Merck KGaA, Incepta Pharmaceuticals Limited, Chugai Pharmaceutical Co., Ltd., BOC Sciences, Northeast Healthcare Co., Ltd, Zydus Cadila Healthcare Ltd, Nhan Sinh Pharmaceuticals Co., Ltd., and others.

Get sample PDF:

By Region

North America

- U.S.
- Canada
- Mexico


- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe


- Japan
- China
- India
- Australia
- Rest of Asia-Pacific


- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA